Review of six major society guidelines: all except ESMO endorse 177Lu-PSMA-617 for PSMA-positive mCRPC after an androgen receptor pathway inhibitor and taxane; NCCN and, more cautiously, EAU accept taxane-naive use after ARPI.
Guidelinen = 6 guidelines
Al-Khanaty et al. Guideline of guidelines: lutetium-177 PSMA radioligand therapy in advanced prostate cancer